101 related articles for article (PubMed ID: 17505083)
1. Modelling the effect of laminar axially directed blood flow on the dissolution of non-occlusive blood clots.
Sersa I; Vidmar J; Grobelnik B; Mikac U; Tratar G; Blinc A
Phys Med Biol; 2007 Jun; 52(11):2969-85. PubMed ID: 17505083
[TBL] [Abstract][Full Text] [Related]
2. A mathematical model for the dissolution of non-occlusive blood clots in fast tangential blood flow.
Sersa I; Tratar G; Mikac U; Blinc A
Biorheology; 2007; 44(1):1-16. PubMed ID: 17502685
[TBL] [Abstract][Full Text] [Related]
3. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
4. Blood clot dissolution dynamics simulation during thrombolytic therapy.
Sersa I; Tratar G; Blinc A
J Chem Inf Model; 2005; 45(6):1686-90. PubMed ID: 16309274
[TBL] [Abstract][Full Text] [Related]
5. Flow through clots determines the rate and pattern of fibrinolysis.
Blinc A; Kennedy SD; Bryant RG; Marder VJ; Francis CW
Thromb Haemost; 1994 Feb; 71(2):230-5. PubMed ID: 8191404
[TBL] [Abstract][Full Text] [Related]
6. The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study.
Wang SS; Chou NK; Chung TW
J Biomed Mater Res A; 2009 Dec; 91(3):753-61. PubMed ID: 19051299
[TBL] [Abstract][Full Text] [Related]
7. Analysis of blood clot degradation fragment sizes in relation to plasma flow velocity.
Bajd F; Vidmar J; Blinc A; Serša I
Gen Physiol Biophys; 2012 Sep; 31(3):237-45. PubMed ID: 23047936
[TBL] [Abstract][Full Text] [Related]
8. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
9. Microscopic clot fragment evidence of biochemo-mechanical degradation effects in thrombolysis.
Bajd F; Vidmar J; Blinc A; Sersa I
Thromb Res; 2010 Aug; 126(2):137-43. PubMed ID: 20580981
[TBL] [Abstract][Full Text] [Related]
10. Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.
Blinc A; Planinsic G; Keber D; Jarh O; Lahajnar G; Zidansĕk A; Demsar F
Thromb Haemost; 1991 May; 65(5):549-52. PubMed ID: 1871717
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
12. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
13. Enhanced clot dissolution in vitro by 1.8-MHz pulsed ultrasound.
Eggers J; Ossadnik S; Seidel G
Ultrasound Med Biol; 2009 Mar; 35(3):523-6. PubMed ID: 19041172
[TBL] [Abstract][Full Text] [Related]
14. Flow-induced permeation of non-occlusive blood clots: an MRI study and modelling.
Grobelnik B; Vidmar J; Tratar G; Blinc A; Sersa I
Eur Biophys J; 2008 Sep; 37(7):1229-33. PubMed ID: 18478224
[TBL] [Abstract][Full Text] [Related]
15. Numerical simulation of in vitro pulsatile flow and its study using FRISK, a rapid phase contrast technique.
Li L; Doyle M; Rayarao G; Kortright E; Ito Y; Anayiotos A
J Magn Reson Imaging; 2007 Sep; 26(3):805-15. PubMed ID: 17729352
[TBL] [Abstract][Full Text] [Related]
16. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
17. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
Blinc A; Keber D; Lahajnar G; Stegnar M; Zidansek A; Demsar F
Thromb Haemost; 1992 Dec; 68(6):667-71. PubMed ID: 1287880
[TBL] [Abstract][Full Text] [Related]
18. Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model.
Spuentrup E; Katoh M; Wiethoff AJ; Buecker A; Botnar RM; Parsons EC; Guenther RW
Rofo; 2007 Nov; 179(11):1166-73. PubMed ID: 17948194
[TBL] [Abstract][Full Text] [Related]
19. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent.
Spuentrup E; Katoh M; Buecker A; Fausten B; Wiethoff AJ; Wildberger JE; Haage P; Parsons EC; Botnar RM; Graham PB; Vettelschoss M; Günther RW
Invest Radiol; 2007 Aug; 42(8):586-95. PubMed ID: 17620942
[TBL] [Abstract][Full Text] [Related]
20. Interactions of fibrinolytic system proteins with lysine-containing surfaces.
McClung WG; Clapper DL; Anderson AB; Babcock DE; Brash JL
J Biomed Mater Res A; 2003 Sep; 66(4):795-801. PubMed ID: 12926031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
